The Current HIV/AIDS Prevention Strategies—Widely Outsmarted by Omitting Realities: A Socio-Critical Analysis in the Context of Powerless Law, Ethics and Asymmetric Interpretation of Human Rights


The HIV pandemic seems to be fading to some degree—but there are regional exceptions. The current liberal prevention strategy with programs aimed at risk reduction interventions in particular for sexual behavior and injecting drug use has been expanded by antiretroviral treatment approaches. It was expected to keep the prevalence of infectious individuals below a certain threshold to curb self-sustaining chains of HIV infections. The introduction of biomedical approaches by ART/HAART with regard to practicing risk reduction behavior has been received as an exemption of responsibility by certain populations who are defined as “at-risk” population. Certain parts of the hard-to-reach, high-risk population have returned to unsafe sex practices leading to careless behavior which in turn has promoted the spread of HIV. This is supported by modern trends in risk societies where with regard to HIV basic principles of ethics and tenets of the Human Rights like “don’t harm other people” have lost any normative power. In addition, with the support of NGOs, legal norms such as protecting the “bodily integrity of individuals” have been ignored, allowing the “passing of HIV to partners” to become socially acceptable behavior. As a whole, in defiance of the endeavors of prevention applied so far, certain societies are exposed to an ongoing spread of HIV.

Share and Cite:

Dennin, R. and Sinn, A. (2015) The Current HIV/AIDS Prevention Strategies—Widely Outsmarted by Omitting Realities: A Socio-Critical Analysis in the Context of Powerless Law, Ethics and Asymmetric Interpretation of Human Rights. World Journal of AIDS, 5, 275-297. doi: 10.4236/wja.2015.53031.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] UNAIDS, Epi Slides (2014)
[2] European Centre for Disease and Prevention Control (ECDC) and WHO (2014) Europe’s HIV Response Falls Short in Curbing Epidemic: 80% More New HIV Cases Compared to 2004. Stockholm-/Copenhagen 27/11/2014. Available Online: Press-Release-Hiv-Aids-Europe-Response-Falls-Short-Curbing-Epidemic-27-November-2014.pdf. Additional information:
European Centre for Disease Prevention and Control/WHO Regional Office for Europe. HIV/AIDS Surveillancein Europe 2013. Stockholm: European Centre for Disease Prevention and Control. d-4d32-b960-af70113dbb90&ID=1217
WHO warns on HIV Spread in Europe and Central Asia. -and-central-asia/a-18092213
[3] European Centre for Disease and Prevention Control (ECDC). 6c-9133-18ff4cb1b568&ID=911
Haar, K. and Amato-Gauci, A.J. (2015) European Men Who Have Sex with Men Still at Risk of HIV Infection Despite Three Decades of Prevention Efforts. Eurosurveillance, 20, pii=21087.
[4] ECDC (2014) Annual Epidemiological Report 2014—STIs including HIV and Blood-Borne Viruses Surveillance Report.
[5] Hall, H.I., An, Q., Tang, T., Song, R., Chen, M., Green, T. and Kang, J. (2015) Prevalence of Diagnosed and Undiagnosed HIV Infection—United States, 2008-2012. Morbidity and Mortality Weekly Report, 64, 657-662. Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, Sexual Transmitted Diseases and Tuberculosis Prevention, Centers for Disease Control and Prevention.
[6] Booth, R., Davis, J., Dvoryak, S., Brewster, J., Strathdee, S. and Latkin, C. (2015) Efficacy of a Network Intervention in Reducing HIV Incidence among people Who Inject Drugs in Ukraine: Preliminary Results from a Clustered Randomized Trial. 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (IAS 2015), Vancouver, Abstract TUAC0402.
[7] Pria, A., Springer, S.A., Copenhaver, M.M. and Altice, F.L. (2010) Neurocognitive Impairment and HIV Risk Factors: A Reciprocal Relationship. AIDS and Behavior, 14, 1213-1226.
[8] Singh, R., Manjot, K. and Deepak, A. (2011) Neurological Complications in Late-Stage Hospitalized Patients with HIV Disease. Annals of Indian Academy of Neurology, 14, 172-177.
[9] McArthur, J.C, Brew, B.J. and Nath, A. (2005) Neurological Complications of HIV Infection. The Lancet Neurology, 4, 543-555.
[10] Bracchi, M., Stuart, D., Castles, R., Khoo, S., Back, D. and Boffito, M. (2015) Increasing Use of “Party Drugs” in People Living with HIV on Antiretrovirals: A Concern for Patient Safety. AIDS, S29, 1585-1592.
[11] Frieden, R.T., Das-Douglas, M., Kellerman, S.E. and Henning, K.J. (2005) Applying Public Health Principles to the HIV Epidemic. New England Journal of Medicine, 353, 2397-2402.
[12] Bayer, R. and Fairchild, A.L. (2006) Changing the Paradigm for HIV Testing—The End of Exceptionalism. New England Journal of Medicine, 355, 647-649.
[13] US Preventive Services Task Force (USPSTF) (2013) Human Immunodeficiency Virus (HIV) Infection: Screening.
[14] Bayer, R. and Oppenheimer, G.M. (2013) Routine HIV Testing. Public Health, and the USPSTF—An End to the Debate. New England Journal of Medicine, 368, 881-884.
[15] Ransomea, Y., Terzianb, A., Addisonc, D., Braunsteinb, S, Myersb, J., Abrahame, B. and Nashc, D. (2015) Expanded HIV Testing Coverage Is Associated with Decreases in Late HIV Diagnoses. AIDS, 29, 1369-1378.
[16] Seth, P., Wang, G., Collins, N.T. and Belcher, L. (2015) Identifying New Positives and Linkage to HIV Medical Care—23 Testing Site Types, United States, 2013. Morbidity and Mortality Weekly Report, 64, 663-667.
[17] Abdool Karim, S.S. (2015) Overcoming Impediments to Global Implementation of Early Antiretroviral Therapy. New England Journal of Medicine, 373, 875-876.
[18] Velter, A., Saboni, L., Le Vu, S. and Lot, F. (2014) Pratiques de dépistage VIH des hommes ayant des rapports sexuels avec des hommes. Apports de l’Enquête presse gays et lesbiennes 2011 [HIV Testing Practices among Men Who Have Sex with Men. Results of the Gay and Lesbian Survey 2011 France]. Bulletin Epidemiologique Hebdomaire, 32-33, 541-547. (Article in French, Abstract in English)
[19] Ferrer, L., Furegato, M., Foschia, J.-P., Folch, C., González, V., Ramarli, D., Casabona, J. and Mirandola, M. (2015) Undiagnosed HIV Infection in a Population of MSM from Six European Cities: Results from the SIALON Project. European Journal of Public Health, 25, 494-500.
[20] Hernando, V., Alvárez-Del Arco, D., Alejos, B., Monge, S., Amato-Gauci, A.J., Noori, T, Pharris, A. and del Amo, J. (2015) HIV Infection in Migrant Populations in the European Union and European Economic Area in 2007-2012: An Epidemic on the Move. Journal of Acquired Immune Deficiency Syndromes, 70, 204-211.
[21] Desgrees du Lou, A., Pannetier, J.A., Ravalihasy, A., Gosselin, A., Supervie, V., Bajos, N., Lert, F., Lydie, N. and Dray-Spira, R. (2015) HIV Acquisition after Arrival in France among Sub-Saharan African Migrants Living with HIV in Paris Area. Estimations from the ANRS PARCOURS Study. 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention, Vancouver, 19-22 July 2015, Abstract WEPDC0103.
[22] Fakoya, I., álvarez-Del Arco, D., Woode-Owusu, M., Monge, S., Rivero-Montesdeoca, Y., Delpech, V., Rice, B., Noori, T., Pharris, A., Amato-Gauci, A.J., Del Amo, J. and Burns, F.M. (2015) A Systematic Review of Post-Migra- tion Acquisition of HIV among Migrants from Countries with Generalised HIV Epidemics Living in Europe: Mplications for Effectively Managing HIV Prevention Programmes and Policy. BMC Public Health, 15, 561.
[23] Schultz, A., Phillips, A.N., Paredes, R., Battegay, M., Rockstroh, J.K., Machala, L., Tomazic, J., Girard, P.M., Januskevica, I., Gronborg-Lauti, K., Lundgreni, J.D. and Alessandro Cozzi-Lepria, A., on Behalf of EuroSIDA in EuroCOORD (2015) HIV Resistance Testing and Detected Drug Resistance in Europe. AIDS, 29, 1379-1389.
[24] Cartwright, C.P. (2006) The Changing Epidemiology of HIV/AIDS at a Minnesota Hospital: Impact of Demographic Change and Viral Diversity. Journal of Medical Virology, 78, S19-S21.
[25] Cooke, G.S. (2015) Hepatitis C Seroprevalence and HIV Co-Infection in Sub-Saharan Africa: A Systematic Review and Meta-Analysis. The Lancet Infectious Diseases, 15, 818-824.
[26] Johnson, W.D., Diaz, R.M., Flanders, W.D., Goodman, M., Hill, A.N., Holtgrave, D., Malow, R. and McClellan, W.M. (2008) Behavioral Interventions to Reduce Risk for Sexual Transmission of HIV among Men Who Have Sex with Men. Cochrane Database of Systematic Reviews, No. 3. Article No.: CD001230.
[27] Crepaz, N., Tungol-Ashmon, M.V., Higa, D.H., Vosburgh, W., Mullins, M.M., Barham, T., Adegbite, A., DeLuca, J.B., Sipe, T.A., White, C.M., Baack, B.N. and Lyles, C.M. (2014) A Systematic Review of Interventions for Reducing HIV Risk Behaviors among People Living with HIV in the United States 1988-2012. AIDS, 28, 633-656.
[28] Paltiel, A.D., Walensky, R.P, Schackman, B.R, Seage III, G.R, Mercincavage, L.M, Weinstein, M.C. and Freedberg, K.A. (2006) Expanded HIV Screening in the United States: Effect on Clinical Outcomes, HIV Transmission, and Costs. Annals of Internal Medicine, 145, 797-806.
[29] WHO (2011) Global Health Sector Strategy on HIV/AIDS 2011-2015.
[30] Crepaz, N. and Marks, G. (2002) Towards an Understanding of Sexual Risk Behavior in People Living with HIV: A Review of Social, Psychological, and Medical Findings. AIDS, 16, 135-149.
[31] Malek, R., Mitchell, H., Furegato, M., Simms, I., Mohammed, H., Nardone, A. and Hughes, G. (2015) Contribution of Transmission in HIV-Positive Men Who Have Sex with Men to Evolving Epidemics of Sexually Transmitted Infections in England: An Analysis Using Multiple Data Sources, 2009-2013. Eurosurveillance, 20, pii=21093.
[32] ECDC (2013) Technical Report, STI and HIV Prevention in Men Who Have Sex with Men in Europe. pdf
[33] Kouyos, R.D., Hasse, B., Calmy, A., Cavassini, M., Furrer, H., Stöckle, M., Vernazza, P.L., Bernasconi, E., Weber, R., Günthard, H.F. and the Swiss HIV Cohort Study (2015) Increases in Condomless Sex in the Swiss HIV Cohort Study. Open Forum Infectious Diseases, 2, ofv077.
[34] Fenton, K. (2013) The Resurgent Global HIV Epidemic in Men Who Have Sex with Men (MSM). Plenary Lecture, BHIVA Autumn Conference, London, UK, 2013. Comment by G. Cairns. aidsmap-news&utm_campaign=aidsmap-news
[35] Executive Summary (2012) Special Issue on HIV in Men who have Sex with Men (MSM). Lancet, 380, No. 9893. Jamaica Coalition for a Healthy Society on Sodomy Laws.
[36] WHO (2011) Global Health Sector Strategy on HIV/AIDS 2011-2015.
[37] Marcellin, F., Lorente, N., Demoulin, B., Carrieri, M.P., Suzan-Monti, M., Roux, P., Lert, F., Sagaon-Teyssier, L., Dray-Spira, R. and Spire, B. (2015) Comparison of Risk Factors in HIV-Infected Men Who Have Sex with Men, Coinfected or Not with Hepatitis C Virus. Sexually Transmitted Infections, 91, 21-23.
[38] Midgard, H., Bjøro, B. and Dalgard, O. (2015) Incidence of Hepatitis C Reinfection Following Sustained Virologic Response—A Seven Year Follow-Up of Scandinavian Patients Infected through Injecting Drug Use. 50th Annual Meeting of the European Association for the Study of the Liver, Vienna, 22-26 April 2015, Abstract O061.
[39] Halkitis, P., Kapadia, F. and Ompad, D. (2015) Incidence of HIV Infection in Young Gay, Bisexual, and Other YMSM: The P18 Cohort Study. JAIDS Journal of Acquired Immune Deficiency Syndromes, 69, 466-473.
[40] Ostrow, D.E., Fox, K.J., Chmiel, J.S., Silvestre, A., Visscher, B.R., Vanable, P.A., Jacobson, L.P. and Strathdee, S.A. (2002) Attitudes towards Highly Active Antiretroviral Therapy Are Associated with Sexual Risk Taking among HIV-Infected and Uninfected Homosexual Men. AIDS, 16, 775-780.
[41] Stolte, I.G., Dukers, N.H., Geskus, R.B., Coutinho, R.A. and de Wit, J.B. (2004) Homosexual Men Change to Risky Sex When Perceiving Less Threat of HIV/AIDS since Availability of Highly Active Antiretroviral Therapy: A Longitudinal Study. AIDS, 18, 303-309.
[42] Bezemer, D., de Wolf, F., Boerlijst, M.C., van Sighem, A., Hollingsworth, T.D., Prinsd, M., Geskus, R.B., Gras, L., Coutinho, R.A. and Fraser, C. (2008) A Resurgent HIV-1 Epidemic among Men Who Have Sex with Men in the Era of Potent Antiretroviral Therapy. AIDS, 22, 1071-1077.
[43] European Centre for Disease and Prevention Control, WHO Europe (2013) HIV/AIDS Surveillance in Europe 2013.
[44] Baggaley, R.F., White, R.G. and Boily, M.-C. (2010) HIV Transmission Risk through Anal Intercourse: Systematic Review, Meta-Analysis and Implications for HIV Prevention. International Journal of Epidemiology, 39, 1048-1063.
[45] UK HIV Drug Resistance Collaboration (2009) Molecular Phylodynamics of the Heterosexual HIV Epidemic in the United Kingdom. PLoS Pathogens, 5, e1000590.
[46] Van de Laar, T., Pybus, O., Bruisten, S., Brown, D., Nelson, M., Bhagani, S., Vogel, M., Baumgarten, A., Chaix, M.L., Fisher, M., Gotz, H., Matthews, G., Neifer, S., White, P., Rawlinson, W., Pol, S., Rockstroh, J., Coutinho, R., Dore, G., Dusheiko, G. and Danta, M. (2009) Evidence of a Large, International Network of HCV Transmission in HIV-Positive Men Who Have Sex with Men. Gastroenterology, 136, 1609-1617.
[47] Sanchez, T.H., Kelley, C.F., Rosenberg, E., Luisi, N., O’Hara, B., Lambert, R., Coleman, R., Frew, P., Salazar, L.F., Tao, S., Clarke, W., Del Rio, C. and Sullivan, P.S. (2014) Lack of Awareness of Human Immunodeficiency Virus (HIV) Infection: Problems and Solutions with Self-Reported HIV Serostatus of Men Who Have Sex with Men. Open Forum Infectious Diseases, 1, ofu084.
[48] Zimbardo, P. (2007) The Lucifer Effect—Understanding How People Turn Evil. Rider, London.
[49] Beck, U. (1992) Risk Society: Towards a New Modernity. Sage, London.
Beck, U. (1986) Risikogesellschaft, Auf dem Weg in eine andere Moderne Taschenbuch. Edition Suhrkamp, Frankfurt. (in German)
[50] Sharp, P.M. and Hahn, B.H. (2011) Origins of HIV and the AIDS Pandemic. Cold Spring Harbor Perspectives in Medicine, 1, a006841.
[51] Heeney, J.L., Dalgleish, A.G. and Weiss, R.A. (2006) Origins of HIV and the Evolution of Resistance to AIDS. Science, 313, 462-466.
[52] Faria, N.R., Rambaut, A., Suchard, M.A., Baele, G., Bedford, T., Ward, M.J., Tatem, A.J., Sousa, J.D., Arinaminpathy, N., Pépin, J., Posada, D., Peeters, M., Pybus, O.G. and Lemey, P. (2014) HIV Epidemiology. The Early Spread and Epidemic Ignition of HIV-1 in Human Populations. Science, 346, 56-61.
[53] Bayer, R. and Fairchild, A.L. (2004) The Genesis of Public Health Ethics. Bioethics, 18, 473-492.
[54] UNAIDS (2006) International Guidelines on HIV/AIDS and Human Rights. 2006 Consolidated Version, Geneva.
[55] WHO Europe. “HIV/AIDS, Data and Statistics”.
[56] Committee on Economic, Social and Cultural Rights (CESCR) (1976) International Covenant on Economic, Social and Cultural Rights.
[57] Gostin, L.O. and Lazzarini, Z. (1997) International Human Rights Law in the AIDS Pandemic. Human Rights and Public Health in the AIDS Pandemic. Oxford University Press, New York, Oxford, 1-42.
[58] Gregson, S., Hallett, T.B., Stover, J. and Ghys, P.D. (2013) Putting the Burden of HIV in Context. AIDS, 27, 2161-2162.
[59] Ortblad, K.F., Lozano, R. and Murray, C.J. (2013) The Burden of HIV: Insights from the Global Burden of Disease Study 2010. AIDS, 27, 2003-2017.
[60] Glass, R.I. (2014) HIV/AIDS and Noncommunicable Disease Comorbidities: Emerging Research Priorities. Journal of Acquired Immune Deficiency Syndromes, 67, S1.
[61] Rueda, S., Law, S. and Rourke, S.B. (2014) Psychological, Mental Health, and Behavioral Issues of Aging with HIV. Current Opinion in HIV and AIDS, 9, 325-331.
[62] Shrestha, R.K., Gardner, L., Marks, G., Craw, J., Malitz, F., Giordano, T.P., Sullivan, M., Keruly, J., Rodriguez, A., Wilson, T.E. and Mugavero, M. (2015) Estimating the Cost of Increasing Retention in Care for HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes, 68, 345-350.
[63] Underhill, K. (2012) Paying for Prevention: Challenges to Health Insurance Coverage for Biomedical HIV Prevention in the United States. American Journal of Law & Medicine, 38, 607-666.
[64] Finance and Economics (2004) The Cost of AIDS: An Imprecise Catastrophe. The Economist (US), 22 May 2004, 82-83.
[65] Nakagawa, F., Miners, A., Smith, C.J., Simmons, R., Lodwick, R.K., Cambiano, V., Lundgren, J.D., Delpech, V. and Phillips, A.N. (2015) Projected Lifetime Healthcare Costs Associated with HIV Infec-tion. PLoS ONE, 10, e01205018.
[66] Stoll, M., Kuhlmann, A., Treskova, M., Bogner, J., Hower, M., Stellbrink, H.J., Heiken, H., Gerschmann, S., Klauke, S., Lutz, T., Degen, O., van Lunzen, J., Bachmann, C., Schmidt, W., Leistner, I., Holm, S., Mahlich, J. and CORSAR-Studiengruppe (2015) Identifikation von Prädiktoren der Krankheitskosten von HIV/AIDS in Deutschland in einem multiplen Regressionsmodell. Deutsch Österreichischer AIDS Kongress, Düsseldorf, 24-27 June 2015, Abstract V7.
[67] Schackman, B.R., Gebo, K.A., Walensky, R.P., Losina, E., Muccio, T., Sax, P.E., Weinstein, M.C., Seage III, G.R., Moore, R.D. and Freedberg, K.A. (2006) The Lifetime Cost of Current Human Immunode-ficiency Virus Care in the United States. Medical Care, 44, 990-997.
[68] Sloan, C.E., Champenois, K., Choisy, P., Losina, E., Walensky, R.P., Schackman, B.R., Ajana, F., Melliez, H., Paltiel, A.D., Freedberg, K.A. and Yazdanpanah, Y., Cost-Effectiveness of Preventing AIDS Complications (CEPAC) Investigators (2012) Newer Drugs and Earlier Treatment: Impact on Lifetime Cost of Care for HIV-Infected Adults. AIDS, 26, 45-56.
[69] Lau, K.A. and Wong, J.J.L. (2013) Current Trends of HIV Recombination Worldwide. Infectious Disease Reports, 5, 15-20.
[70] UNAIDS. Criminalization of HIV Transmission—Policy Brief. ent /2008/20080731_jc1513_policy_criminalization_en.pdf
[71] NAM Aidsmap (2015) Challenges Associated with Disclosing One’s HIV-Positive Status.
[72] Upton, C.T., Taiwo, B. and Robertson, K.R. (2013) HIV-Associated Neurocognitive Disorders. Future Virology, 8, 469-475.
[73] Open Society Foundations (2008) Ten Reasons to Oppose the Criminalization of HIV Exposure or Transmission.
[74] Rayment, M., on Behalf of the BASHH and BHIVA Audit Committees (2013) HIV Partner Notification: Findings of the Joint BHIVA/BASHH Audit. For the 2013 BHIVA Autumn Conference Presentations. London 14-15 November 2013. Comment by G. Cairns “Partner Notification Highly Effective at Finding New HIV Cases, but a Third Who Could Be Tested Are Missed.”
[75] Zhu, T., Korber, B.T., Nahmias, A.J., Hooper, E., Sharp, P.M. and Ho, D.D. (1998) An African HIV-1 Sequence from 1959 and Implications for the Origin of the Epidemic. Nature, 391, 594-597.
[76] McCarthy, K.R., Kirmaier, A., Autissier, P. and Johnson, W.E. (2015) Evolutionary and Functional Analysis of Old World Primate TRIM5 Reveals the Ancient Emergence of Primate Lentiviruses and Convergent Evolution Targeting a Conserved Capsid Interface. PLoS Pathogens, 11, e1005085.
[77] Mousseau, G., Kessing, C.F., Fromentin, R., Trautmann, L., Chomont, N. and Valente, S.T. (2015) The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency. mBio, 6, e00465-15.
[78] Sturdevant, C.B., Joseph, S.B., Schnell, G., Price, R.W., Swanstrom, R. and Spudich, S. (2015) Compartmentalized Replication of R5 T Cell-Tropic HIV-1 in the Central Nervous System Early in the Course of Infection. PLoS Pathogens, 11, e1004720.
Affiliation: Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill.
[79] Agosto, L.M., Uchil, P.D. and Mothes, W. (2015) HIV Cell-to-Cell Transmission: Effects on Pathogenesis and Antiretroviral Therapy. Trends in Microbiology, 23, 289-295.
[80] Gaardbo, J.C., Hartling, H.J., Gerstoft, J. and Nielsen, S.D. (2012) Thirty Years with HIV Infection—Nonprogression Is Still Puzzling: Lessons to Be Learned from Controllers and Long-Term Nonprogressors. AIDS Research and Treatment, 2012, Article ID: 161584.
[81] Maldarelli, F., Kearney, M., Palmer, S., Stephens, R., Mican, J.A., Polis, M.A., Davey, R.T., Kovacs, J., Shao, W., Rock-Kress, D., Metcalf, J.A., Rehm, C., Greer, S.E., Lucey, D.L., Danley, K., Alter, H., Mellors, J.W. and Coffin, J.M. (2013) HIV Populations Are Large and Accumulate High Genetic Diversity in a Nonlinear Fashion. Journal of Virology, 87, 10313-10323.
[82] Mbisa, J.L., Fearnhill, E., Dunn, D.T., Pillay, D., Asboe, D. and Cane, P.A., on Behalf of the UK HIV Drug Resistance Database (2015) Evidence of Self-Sustaining Drug Resistant HIV-1 Lineages among Untreated Patients in the UK. Clinical Infectious Diseases, 61, 829-836.
[83] Kouyos, R.D., Huldrych, F. and Günthard, H.F. (2015) Editorial Commentary: The Irreversibility of HIV Drug Resistance. Clinical Infectious Diseases, 61, 837-839.
[84] Turk, G. and Carobene, M.G. (2015) Deciphering How HIV-1 Intersubtype Recombination Shapes Viral Fitness and Disease Progression. EBioMedicine, 2, 188-189.
[85] Peeters, M. (2015) Recombinant HIV Sequences: Their Role in the Global Epidemic.
[86] Perrin, L., Kaiser, L. and Yerly, S. (2003) Travel and the Spread of HIV-1 Genetic Variants. Lancet Infectious Diseases, 3, 22-27.
[87] Angelis, K., Albert, J., Mamais, I., Magiorkinis, G., Hatzakis, A., Hamouda, O., Struck, D., Vercauteren, J., Wensing, A.M.J., Alexiev, I., Åsjö, B., Balotta, C., Camacho, R.J., Coughlan, S., Griskevicius, A., Grossman, Z., Horban, A., Kostrikis, L.G., Lepej, S., Liitsola, K., Linka, M., Nielsen, C., Otelea, D., Paredes, R., Poljak, M., Puchhammer-Stöckl, E., Schmit, J.-C., Sönnerborg, A., Staneková, D., Stanojevic, M., Boucher, C.A.B., Kaplan, L., Vandamme, A.-M. and Paraskevis, D. (2014) Global Dispersal Pattern of HIV Type 1 Subtype CRF01_AE: A Genetic Trace of Human Mobility Related to Heterosexual Sexual Activities Centralized in Southeast Asia. The Journal of Infectious Diseases, 211, 1735-1744.
[88] Kouri, V., Khouri, R., Alemán, Y., Abrahantes, Y., Vercauteren, J., Pineda-Peña, A.-C., Theys, K., Megens, S., Moutschen, M., Pfeifer, N., Van Weyenbergh, J., Pérez, A.B., Pérez, J., Pérez, L., Van Laethem, K. and Vandamme, A.-M. (2015) CRF19_cpx Is an Evolutionary Fit HIV-1 Variant Strongly Associated with Rapid Progression to AIDS in Cuba. EBioMedicine, 2, 244-254.
[89] Luft, L.A.M., Gill, M.J. and Church, D.L. (2011) HIV-1 Viral Diversity and Its Implications for Viral Load Testing: Review of Current Platforms. International Journal of Infectious Diseases, 15, e661-e670.
[90] Fox, J., Castro, H., Kaye, S., McClure, M., Weber, J.N. and Fidler, S., UK Collaborative Group on HIV Drug Resistance (2010) Epidemiology of Non-B Clade Forms of HIV-1 in Men Who Have Sex with Men in the UK. AIDS, 24, 2397-2401.
[91] The UK Collaborative Group on HIV Drug Resistance (2014) The Increasing Genetic Diversity of HIV-1 in the UK, 2002-2010. AIDS, 28, 773-780.
[92] Cohen, J. (2010) Tracing the Regional Rise of HIV. Science, 329, 161.
[93] Lihana, R.W., Ssemwanga, D., Abimiku, A. and Ndembi, N. (2012) Update on HIV-1 Diversity in Africa: A Decade in Review. AIDS Reviews, 14, 83-100.
[94] Lau, K.A., Wang, B. and Saksena, N.K. (2007) Emerging Trends of HIV Epidemiology in Asia. AIDS Reviews, 9, 218-229.
[95] Abrahams, M.-R., Treurnicht, F.K., Ngandu, N.K., Goodier, S.A., Marais, J.C., Bredell, H., Thebus, R., de Assis Rosa, D., Mlisana, K., Seoighe, C., Karim, S.A., Gray, C.M. and Williamson, C., the Centre for the AIDS Program of Research in South Africa Acute Infection Study Team and the Center for HIV-AIDS Vaccine Immunology Consortium (2013) Rapid, Complex Adaptation of Transmitted HIV-1 Full-Length Genomes in Subtype C-Infected Individuals with Differing Disease Progression. AIDS, 27, 507-518.
[96] Deogratiusa, S., Lyagoba, F., Ndembi, N., Mayanja, B.N., Larke, N., Wang, S., Baalwa, J., Williamson, C., Grosskurth, H. and Kaleebua, P. (2011) Multiple HIV-1 Infections with Evidence of Recombination in Heterosexual Partnerships in a Low Risk Rural Clinical Cohort in Uganda. Virology, 411, 113-131.
[97] Fauci, A.S. and Marston, H.D. (2015) Focusing to Achieve a World without AIDS. JAMA, 313, 357-358.
[98] UNAIDS (2014) Fast-Track: Ending the AIDS Epidemic by 2030.
[99] Lima, V.D., Bangsberg, D.R., Harrigan, P.R., Deeks, S.G., Yip, B., Hogg, R.S. and Montaner, J.S. (2010) Risk of Viral Failure Decline with Duration of Suppression on Highly Antiretroviral Therapy Irrespective of Adherence Level. Journal of Acquired Immune Deficiency Syndromes, 55, 460-465.
[100] McCormack, S. and Dunn, D., PROUD Study Group (2015) Pragmatic Open-Label Randomised Trial of Preexposure Prophylaxis: The PROUD Study. Abstract 22LB.
Molina, J.M., Capitant, C., Spire, B., Pialoux, G., Chidiac, C., Charreau, I., et al., ANRS Ipergay Study Group (2015) On Demand PrEP with Oral TDF-FTC in MSM: Results of the ANRS Ipergay Trial, Abstract 23LB. Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, 23-24 February 2015. Comment by Jim Kling.
[101] Keith, A. (2011) Is HIV Drug Resistance Spreading? Early Warning Signals Say “Yes”. Comments from the Eighteenth Conference on Retroviruses and Opportunistic Infections, Boston, 2011.
[102] World Health Organization (2012) WHO HIV Drug Resistance Report 2012.
[103] Haberer, J.E., Bangsberg, D.R., Baeten, J.M., Curran, K., Koechlin, F., Amico, K.R., Anderson, P., Mugo, N., Venter, F., Goicochea, P., Caceres, C. and O’Reilly, K. (2015) Defining Success with HIV Pre-Exposure Prophylaxis: A Prevention-Effective Adherence Paradigm. AIDS, 29, 1277-1285.
[104] McNairy, M.L. and El-Sadr, W.M. (2014) Antiretroviral Therapy for the Prevention of HIV Transmission: What Will It Take? Clinical Infectious Diseases, 58, 1003-1011.
[105] Beyrer, Ch., et al. (2015) The Vancouver Consensus. The 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Vancouver, 19-22 July 2015.
[106] Martin, M., Vanichseni, S., Suntharasamai, P., Sangkum, U., Mock, P.A., Leethochawalit, M., Chiamwongpaet, S., Curlin, M.E., Na-Pompet, S., Warapronmongkholkul, A., Kittimunkong, S., Gvetadze, R.J., McNicholl, J.M., Paxton, L.A. and Choopanya, K., the Bangkok Tenofovir Study Group (2015) The Impact of Adherence to Preexposure Prophylaxis on the Risk of HIV Infection among People Who Inject Drugs. AIDS, 29, 819-824.
[107] Winand, R., Theys, K., Eusébio, M., Aerts, J., Camacho, R.J., Gomes, P., Suchard, M.A., Vandamme, A.-M., Abecasis, A.B. and Portuguese HIV-1 Resistance Study Group (2015) Assessing Transmissibility of HIV-1 Drug Resistance Mutations from Treated and from Drug-Naive Individuals. AIDS, S29, 2045-2052.
[108] Gupta, R.K., Jordan, M.R, Sultan, B.J., Hill, A., Davis, D.H.J., Gregson, J., Sawyer, A.W., Hamers, R.L., Ndembi, N., Pillay, D. and Bertagnolio, S. (2012) Global Trends in Antiretroviral Resistance in Treatment-Naïve Individuals with HIV after Rollout of Antiretroviral Treatment in Resource-Limited Settings: A Global Collaborative Study and Meta-Regression Analysis. Lancet, 380, 1250-1258.
[109] McFaul, K.M., Lim, C., Jones, R., Asboe, D., Pozniak, A., Sonecha, S., Boffito, M. and Nwokolo, N. (2014) Transmitted Antiretroviral Drug Resistance in Treatment Na?ve HIV-Infected Persons in London in 2011 to 2013. Journal of the International AIDS Society, 17, 19747.
[110] Pillay, D. and Fisher, M. (2007) Primary HIV Infection, Phylogenetics, and Antiretroviral Prevention. The Journal of Infectious Diseases, 195, 924-926.
[111] Pilcher, H. (2004) HIV Outpaces Global Response.
2004 Report on the Global AIDS Epidemic. Joint United National Programme on HIV/AIDS.
[112] El-Sadr, W.M., Harripersaud, K. and Bayer, R. (2014) End of AIDS—Hyper versus Hope. Science, 345, 166.
[113] Milstein B. (2006) An Introduction to Syndemics: Implications for Health Promotion. Syndemics Prevention Network, Centers for Disease Control and Prevention.
[114] Merson, M.H., O’Malley, J., Serwadda, D. and Apisuk, C. (2008) The History and Challenge of HIV Prevention. Lancet, 372, 475-488.
[115] Kelly, J.A. (2000) HIV Prevention Interventions with Gay or Bisexual Men and Youth. AIDS, 14, S34-S39.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.